Bristol Myers Squibb Extends $2B+ AI Drug Discovery Pact with Insitro to Advance ALS Research
SHERIDAN, WYOMING – October 15, 2025 – Bristol Myers Squibb (BMS) has expanded its artificial intelligence-driven collaboration with insitro, reinforcing its long-term strategy to accelerate therapeutic development in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The renewed deal underscores a shared commitment to leveraging AI and advanced chemistry platforms to unlock new pathways in ALS drug discovery.
AI-Powered Extension Strengthens a Five-Year Alliance
The latest extension adds another year to the 2020 collaboration, with BMS investing up to $20 million to continue joint research using insitro’s advanced ChemML platform. The total deal value could exceed $2 billion through potential discovery, development, and commercial milestones, as well as royalties on any approved therapies.